Skip to main content

Table 3 Patient reported outcomes

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

  Baseline (Visit 2) End of period 1 End of period 2 p-value*
ITEQ     
Sequence A No insulin Tx 74.2 ± 11.8 73.3 ± 12.9 0.52
Sequence B No insulin Tx 73.0 ± 13.7 73.2 ± 12.0 0.74
p-value**   0.42 0.97  
DTSQs Hyperglycemia     
Sequence A 4.2 ± 1.53 2.2 ± 1.57 2.3 ± 1.76 n.a.
Sequence B 4.2 ± 1.60 2.2 ± 1.73 2.1 ± 1.70 n.a.
p-value**   1.0 0.32  
DTSQs Hypoglycemia     
Sequence A 0.7 ± 1.32 1.2 ± 1.57 1.3 ± 1.68 n.a.
Sequence B 0.6 ± 1.15 1.0 ± 1.47 1.1 ± 1.52 n.a.
p-value**   0.25 0.29  
  Baseline (Visit 2) ∆ from baseline ∆ from end of period 1 p-value*
PAID     
Sequence A 21.3 ± 15.7 −5.1 ± 11.4 0.7 ± 10.4 <0.0001
Sequence B 23.3 ± 15.4 −4.4 ± 14.8 0.5 ± 11.7 0.0049
p-value**   0.61 0.89  
SF-12® mental health     
Sequence A 50.2 ± 9.34 0.5 ± 7.91 0.4 ± 7.56 0.68
Sequence B 49.8 ± 10.5 0.8 ± 9.21 −0.6 ± 8.59 0.24
p-value**   0.77 0.34  
SF-12® physical health     
Sequence A 50.5 ± 9.06 0.5 ± 7.94 −0.3 ± 8.04 n.a.
Sequence B 49.4 ± 9.20 0.9 ± 7.99 0.6 ± 7.29 n.a.
p-value**   0.70 0.36  
EQ-5D descriptive     
Sequence A 0.89 ± 0.16 −0.009 ± 0.1727 −0.005 ± 0.1787 0.91
Sequence B 0.900 ± 0.1682 0.001 ± 0.1606 −0.009 ± 0.1637 0.88
p-value**   0.62 0.85  
EQ-5D VAS     
Sequence A 0.867 ± 0.1730 −0.000 ± 0.1646 0.001 ± 0.1557 n.a.
Sequence B 0.862 ± 0.1819 0.009 ± 0.1655 −0.013 ± 0.1566 n.a.
p-value**   0.64 0.45  
DTSQs     
Sequence A 27.9 ± 7.72 3.2 ± 8.04 −0.8 ± 6.38 <0.0001
Sequence B 27.2 ± 7.37 2.1 ± 7.36 0.3 ± 6.92 0.0420
p-value**   0.22 0.16  
  1. Legend: * Paired t-test was applied for comparison of treatments within sequence; ** Unpaired t-test was applied for comparison of treatments in periods; Sequence A: starting with insulin glargine (GLAR) and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin glargine (GLAR)